Compositions and methods for treating ischemia and ischemia-reperfusion injury
AssigneeIschemix LLC
InventorsAlexander Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan S. Lader
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula I: and methods of using such compounds to activate cytoprotective kinases. The values and preferred values of the variables in Structural Formula I are defined herein.
Claims14
A method of activating at least one cytoprotective kinase in a cell, comprising contacting a cell with an effective amount of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein R1 and R2 in the compound are each independently H or a hydrolyzable group, and wherein the compound has a percent optical purity of at least 90% by weight relative to the other stereoisomers.
A method of inhibiting apoptosis in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein R1 and R2 in the compound are each independently H or a hydrolyzable group, and wherein the compound or pharmaceutically acceptable salt thereof is at least 90% enantiomerically pure.
A method of preventing cytosolic calcium overload in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein R1 and R2 in the compound are each independently H or a hydrolyzable group, and wherein the compound or pharmaceutically acceptable salt thereof is at least 90% enantiomerically pure.
A method of increasing peroxyl radical absorbance in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein R1 and R2 in the compound are each independently H or a hydrolyzable group, and wherein the compound or pharmaceutically acceptable salt thereof is at least 90% enantiomerically pure.
Dependencies are inferred from the claim text.